High-dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II study.
Bottom Line: Disease progression was observed in 11 patients.The mean survival time was 26.7 months.We concluded that high-dose PBT with concurrent chemotherapy is safe to use in the treatment of unresectable Stage III NSCLC.
Affiliation: Department of Radiation Oncology, University of Tsukuba, Tsukuba, Ibaraki, Japan.Show MeSH
Related in: MedlinePlus
Mentions: At the time of analysis, nine patients were alive. The median follow-up period for the survivors was 21.7 months (range: 7–39 months). The mean survival time was 26.7 months (95% confidence interval (CI): 19.5–33.9 months), and the 2-year overall survival time was 51% (95% CI: 21.7–80.3%) (Fig. 1). The median progression-free survival was 10.2 months (95% CI: 8.0–12.4 months), and the 1- and 2-year progression-free survival rates were 24.2% (95% CI: 1.0–48%) and 16.1% (95% CI: 0–36.6%), respectively (Fig. 2). The acute toxicities are presented in Table 2. Among the non-hematologic acute toxicities, Grade 3 pneumonitis was observed in two patients and was diagnosed as infectious pneumonia and obstructive pneumonia on the basis of clinical course and image findings. No severe radiation pneumonitis was observed. Grade 3 esophagitis and skin reactions were observed in one and two patients, respectively. Among the hematologic toxicities, severe ( ≥ Grade 3) leukocytopenia, neutropenia and thrombocytopenia were observed in 10 patients, 7 patients and 1 patient, respectively. In particular, Grade 4 neutropenia was observed in four patients (26.7%). The full doses of the first and second courses of chemotherapy were completed in 13 (87%) and eight (53%) patients, respectively.Table 2.
Affiliation: Department of Radiation Oncology, University of Tsukuba, Tsukuba, Ibaraki, Japan.